HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) An erratum has been published Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bruserud, O. Articles by Ernst, P. Search for Related Content PubMed PubMed Citation Articles by Bruserud, O. Articles by Ernst, P.

New Strategies in the Treatment of Acute Myelogenous Leukemia: Mobilization and Transplantation of Autologous Peripheral Blood Stem Cells in Adult Patients

^a Division for Hematology, Department of Medicine, Haukeland University Hospital and The University of Bergen, Bergen, Norway;
^b Division for Hematology, Department of Medicine, The National Hospital, Oslo, Norway

Key Words. Acute myelogenous leukemia • Autologous bone marrow transplantation • Peripheral blood stem cell • Minimal residual disease

Øystein Bruserud, M.D., Medical Department, Haukeland University Hospital, N-5021 Bergen, Norway. Telephone 47-55-29-80-60; Fax 47-55-97-29-50; e-mail: oystein.bruserud{at}haukeland.no

During the last decade high-dose Ara-C (HIDAC; single doses of 3 g/m²) and autologous stem cell transplantation have been increasingly used as postremission therapy in adult acute myelogenous leukemia (AML). Controlled clinical trials have demonstrated a long-term disease-free survival of 40%-50% for patients treated with at least two courses of HIDAC. Other studies have demonstrated that postremission autologous bone marrow transplantation results in a disease-free survival equal to or better than conventional chemotherapy. However, autotransplantation with mobilized peripheral blood stem cells (PBSC) would now be preferred instead of autologous bone marrow, due to the shorter hematopoietic reconstitution period. The results reviewed in the present article suggest that HIDAC and autologous PBSC transplantation can be combined in the postremission treatment of adult AML, and this combination therapy may also reduce minimal residual disease and the risk of posttransplant relapse. From the available studies it cannot be concluded whether graft purging further reduces the relapse risk. However, the possible advantage of combination therapy with repeated courses of HIDAC and autologous PBSC transplantation needs to be demonstrated in prospective clinical trials before it can be recommended as a part of the routine treatment in AML.

This article has been cited by other articles:

				A. Antignani and R. J. Youle The Cytokine, Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF), Can Deliver Bcl-XL as an Extracellular Fusion Protein to Protect Cells from Apoptosis and Retain Differentiation Induction J. Biol. Chem., April 13, 2007; 282(15): 11246 - 11254. [Abstract] [Full Text] [PDF]

				N. Anensen, A. M. Oyan, J.-C. Bourdon, K. H. Kalland, O. Bruserud, and B. T. Gjertsen A Distinct p53 Protein Isoform Signature Reflects the Onset of Induction Chemotherapy for Acute Myeloid Leukemia. Clin. Cancer Res., July 1, 2006; 12(13): 3985 - 3992. [Abstract] [Full Text] [PDF]

				Y. Zhang, M. I. Dawson, Y. Ning, L. Polin, R. E. Parchment, T. Corbett, A. N. Mohamed, K.-C. Feng, L. Farhana, A. K. Rishi, et al. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog Blood, November 15, 2003; 102(10): 3743 - 3752. [Abstract] [Full Text] [PDF]

				P. O. Iversen, C. A. Drevon, and J. E. Reseland Prevention of leptin binding to its receptor suppresses rat leukemic cell growth by inhibiting angiogenesis Blood, December 1, 2002; 100(12): 4123 - 4128. [Abstract] [Full Text] [PDF]